Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy IONS?
Source: Newsfilter
- FDA Priority Review: Ionis Pharmaceuticals announced that its New Drug Application for zilganersen, targeting Alexander disease, has been accepted for Priority Review by the FDA, with a PDUFA date set for September 22, 2026, indicating the drug's potential to be the first treatment for this condition and addressing a significant unmet need in the market.
- Clinical Trial Results: In a pivotal study involving 54 participants, the 50 mg dose of zilganersen demonstrated a statistically significant 33.3% improvement in gait speed at week 61 (p=0.0412), highlighting the drug's important clinical relevance in enhancing patient mobility.
- Market Potential: Alexander disease is a rare and often fatal neurological disorder, occurring in approximately 1 in 1 to 3 million people globally, and the successful launch of zilganersen would fill a critical gap in treatment options, thereby strengthening Ionis's market position in neurology.
- Strategic Milestone: If approved, zilganersen will mark Ionis's first independent commercial launch in neurology, which will not only drive growth in this sector but also support the company's strategic goal of continuously developing transformative medicines for serious diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IONS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IONS
Wall Street analysts forecast IONS stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 72.150
Low
65.00
Averages
92.67
High
110.00
Current: 72.150
Low
65.00
Averages
92.67
High
110.00
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: The U.S. FDA has approved the High Dose SPINRAZA (nusinersen), which includes 50 mg/5 mL and 28 mg/5 mL doses, aimed at providing a more effective treatment option for spinal muscular atrophy (SMA) patients, with availability expected in the coming weeks, marking a significant advancement in the treatment landscape.
- Clinical Data Support: The high dose regimen is backed by clinical data from the DEVOTE study, which demonstrated statistically significant improvements in motor function for treatment-naïve infants, with a mean difference of 26.19 points on the CHOP-INTEND scale (+15.1 vs. -11.1, p<0.0001), offering new hope for SMA patients.
- Optimized Treatment Protocol: The new regimen features an accelerated loading phase, allowing treatment-naïve patients to receive two 50 mg injections 14 days apart, followed by 28 mg maintenance doses every four months, designed to enhance treatment convenience and effectiveness to meet urgent patient needs.
- Global Expansion: High Dose SPINRAZA has not only been approved in the U.S. but also in the European Union, Switzerland, and Japan, with Biogen collaborating with global regulatory authorities to advance this new treatment option to meet the diverse needs of SMA patients.
See More
GSK Seeks EMA Approval for Bepirovirsen in Chronic Hepatitis B Treatment
- Regulatory Submission Accepted: GSK plc announced that the European Medicines Agency has accepted its marketing authorization application for bepirovirsen, an antiviral drug for adults with chronic hepatitis B, marking a significant milestone in the company's drug development efforts.
- Clinical Trial Results: The application is based on positive outcomes from the B-Well 1 and B-Well 2 Phase III trials, indicating the drug's potential efficacy and safety in treating chronic hepatitis B, which could address a significant unmet medical need.
- Collaborative Development: GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated on its development, showcasing the company's strategic partnerships in advancing innovative therapeutics.
- Market Potential Assessment: Although the drug is not yet approved anywhere globally, successful market entry could open new opportunities for GSK in the chronic hepatitis B treatment space, enhancing its competitive position in the biopharmaceutical industry.
See More
Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning
- Pricing Strategy: Ionis Pharmaceuticals has lowered the price of Tryngolza ahead of the sHTG decision, with analysts suggesting that this move will enhance sales potential and attract more patients, thereby increasing market share.
- Sales Potential Increase: By reducing the price, Ionis aims to stand out in a competitive market, with analysts predicting that this action will significantly boost Tryngolza's sales over the coming quarters, further solidifying its position in the treatment landscape.
- Competitive Positioning Optimization: This price adjustment is not only a response to market demand but may also prompt competitors to reassess their pricing strategies, potentially impacting the overall industry price structure, allowing Ionis to gain a larger market advantage.
- Market Reaction Expectations: Analysts are generally optimistic about Tryngolza's market prospects, believing that the price reduction will enhance patient acceptance and drive sales growth, indicating Ionis's keen awareness of market dynamics.
See More
When Insider Selling Can Be Positive: 2 Stocks to Keep an Eye On
Insider Selling Trends: Insider selling is increasing, with executives from Waste Management and Ionis Pharmaceuticals selling shares, indicating a potential shift in stock performance outlooks despite strong growth prospects.
Stock Performance and Dividends: Waste Management's stock has risen significantly, driven by insider selling, while the company maintains a strong dividend yield, suggesting a solid investment opportunity for new investors.
Ionis Pharmaceuticals Outlook: Ionis Pharmaceuticals faces a cautious outlook due to declining sales of its key products, despite having a strong pipeline and potential for future growth.
Analyst Sentiment: Analysts are generally optimistic about both companies, with a consensus rating of "Moderate Buy" for Ionis and a positive sentiment towards Waste Management, indicating potential for continued stock price appreciation.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: The US FDA has granted Priority Review to Ionis Pharmaceuticals' NDA for zilganersen, with an action date set for September 22, accelerating the drug's potential market entry for treating the rare neurological condition, Alexander disease.
- Clinical Trial Results: In a pivotal study, children and adults receiving 50 mg of zilganersen demonstrated significant stabilization in gait speed at week 61, as measured by the 10-Meter Walk Test, indicating the drug's potential clinical value in improving patient functionality compared to the control group.
- Disease Impact: Alexander disease affects 1 in 1 to 3 million people globally, characterized by loss of functional mobility and independence, as well as the inability to control large movements, swallowing, and airway protection, highlighting the severity of the condition and the urgent need for effective treatments.
- Market Outlook: Ionis Pharmaceuticals outlines a peak sales target of over $2 billion for olezarsen, with optimistic projections for 2026 driven by new launches and pipeline catalysts, further bolstering investor confidence in the company's future growth prospects.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: Ionis Pharmaceuticals announced that its New Drug Application for zilganersen, targeting Alexander disease, has been accepted for Priority Review by the FDA, with a PDUFA date set for September 22, 2026, indicating the drug's potential to be the first treatment for this condition and addressing a significant unmet need in the market.
- Clinical Trial Results: In a pivotal study involving 54 participants, the 50 mg dose of zilganersen demonstrated a statistically significant 33.3% improvement in gait speed at week 61 (p=0.0412), highlighting the drug's important clinical relevance in enhancing patient mobility.
- Market Potential: Alexander disease is a rare and often fatal neurological disorder, occurring in approximately 1 in 1 to 3 million people globally, and the successful launch of zilganersen would fill a critical gap in treatment options, thereby strengthening Ionis's market position in neurology.
- Strategic Milestone: If approved, zilganersen will mark Ionis's first independent commercial launch in neurology, which will not only drive growth in this sector but also support the company's strategic goal of continuously developing transformative medicines for serious diseases.
See More
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: The U.S. FDA has approved the High Dose SPINRAZA (nusinersen), which includes 50 mg/5 mL and 28 mg/5 mL doses, aimed at providing a more effective treatment option for spinal muscular atrophy (SMA) patients, with availability expected in the coming weeks, marking a significant advancement in the treatment landscape.
- Clinical Data Support: The high dose regimen is backed by clinical data from the DEVOTE study, which demonstrated statistically significant improvements in motor function for treatment-naïve infants, with a mean difference of 26.19 points on the CHOP-INTEND scale (+15.1 vs. -11.1, p<0.0001), offering new hope for SMA patients.
- Optimized Treatment Protocol: The new regimen features an accelerated loading phase, allowing treatment-naïve patients to receive two 50 mg injections 14 days apart, followed by 28 mg maintenance doses every four months, designed to enhance treatment convenience and effectiveness to meet urgent patient needs.
- Global Expansion: High Dose SPINRAZA has not only been approved in the U.S. but also in the European Union, Switzerland, and Japan, with Biogen collaborating with global regulatory authorities to advance this new treatment option to meet the diverse needs of SMA patients.
See More
GSK Seeks EMA Approval for Bepirovirsen in Chronic Hepatitis B Treatment
- Regulatory Submission Accepted: GSK plc announced that the European Medicines Agency has accepted its marketing authorization application for bepirovirsen, an antiviral drug for adults with chronic hepatitis B, marking a significant milestone in the company's drug development efforts.
- Clinical Trial Results: The application is based on positive outcomes from the B-Well 1 and B-Well 2 Phase III trials, indicating the drug's potential efficacy and safety in treating chronic hepatitis B, which could address a significant unmet medical need.
- Collaborative Development: GSK licensed bepirovirsen from Ionis Pharmaceuticals and collaborated on its development, showcasing the company's strategic partnerships in advancing innovative therapeutics.
- Market Potential Assessment: Although the drug is not yet approved anywhere globally, successful market entry could open new opportunities for GSK in the chronic hepatitis B treatment space, enhancing its competitive position in the biopharmaceutical industry.
See More
Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning
- Pricing Strategy: Ionis Pharmaceuticals has lowered the price of Tryngolza ahead of the sHTG decision, with analysts suggesting that this move will enhance sales potential and attract more patients, thereby increasing market share.
- Sales Potential Increase: By reducing the price, Ionis aims to stand out in a competitive market, with analysts predicting that this action will significantly boost Tryngolza's sales over the coming quarters, further solidifying its position in the treatment landscape.
- Competitive Positioning Optimization: This price adjustment is not only a response to market demand but may also prompt competitors to reassess their pricing strategies, potentially impacting the overall industry price structure, allowing Ionis to gain a larger market advantage.
- Market Reaction Expectations: Analysts are generally optimistic about Tryngolza's market prospects, believing that the price reduction will enhance patient acceptance and drive sales growth, indicating Ionis's keen awareness of market dynamics.
See More
When Insider Selling Can Be Positive: 2 Stocks to Keep an Eye On
Insider Selling Trends: Insider selling is increasing, with executives from Waste Management and Ionis Pharmaceuticals selling shares, indicating a potential shift in stock performance outlooks despite strong growth prospects.
Stock Performance and Dividends: Waste Management's stock has risen significantly, driven by insider selling, while the company maintains a strong dividend yield, suggesting a solid investment opportunity for new investors.
Ionis Pharmaceuticals Outlook: Ionis Pharmaceuticals faces a cautious outlook due to declining sales of its key products, despite having a strong pipeline and potential for future growth.
Analyst Sentiment: Analysts are generally optimistic about both companies, with a consensus rating of "Moderate Buy" for Ionis and a positive sentiment towards Waste Management, indicating potential for continued stock price appreciation.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: The US FDA has granted Priority Review to Ionis Pharmaceuticals' NDA for zilganersen, with an action date set for September 22, accelerating the drug's potential market entry for treating the rare neurological condition, Alexander disease.
- Clinical Trial Results: In a pivotal study, children and adults receiving 50 mg of zilganersen demonstrated significant stabilization in gait speed at week 61, as measured by the 10-Meter Walk Test, indicating the drug's potential clinical value in improving patient functionality compared to the control group.
- Disease Impact: Alexander disease affects 1 in 1 to 3 million people globally, characterized by loss of functional mobility and independence, as well as the inability to control large movements, swallowing, and airway protection, highlighting the severity of the condition and the urgent need for effective treatments.
- Market Outlook: Ionis Pharmaceuticals outlines a peak sales target of over $2 billion for olezarsen, with optimistic projections for 2026 driven by new launches and pipeline catalysts, further bolstering investor confidence in the company's future growth prospects.
See More
Ionis Pharmaceuticals Receives FDA Priority Review for Zilganersen
- FDA Priority Review: Ionis Pharmaceuticals announced that its New Drug Application for zilganersen, targeting Alexander disease, has been accepted for Priority Review by the FDA, with a PDUFA date set for September 22, 2026, indicating the drug's potential to be the first treatment for this condition and addressing a significant unmet need in the market.
- Clinical Trial Results: In a pivotal study involving 54 participants, the 50 mg dose of zilganersen demonstrated a statistically significant 33.3% improvement in gait speed at week 61 (p=0.0412), highlighting the drug's important clinical relevance in enhancing patient mobility.
- Market Potential: Alexander disease is a rare and often fatal neurological disorder, occurring in approximately 1 in 1 to 3 million people globally, and the successful launch of zilganersen would fill a critical gap in treatment options, thereby strengthening Ionis's market position in neurology.
- Strategic Milestone: If approved, zilganersen will mark Ionis's first independent commercial launch in neurology, which will not only drive growth in this sector but also support the company's strategic goal of continuously developing transformative medicines for serious diseases.
See More
